Alnylam Pharmaceuticals’ (ALNY) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a report released on Wednesday,Benzinga reports. They currently have a $320.00 price objective on the biopharmaceutical company’s stock.

A number of other brokerages have also commented on ALNY. Sanford C. Bernstein cut their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Raymond James upped their target price on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Barclays raised their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Scotiabank dropped their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a report on Friday, February 14th. Finally, Morgan Stanley increased their target price on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $304.26.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $243.86 on Wednesday. The firm has a market capitalization of $31.57 billion, a PE ratio of -112.38 and a beta of 0.35. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The firm’s fifty day simple moving average is $254.33 and its 200 day simple moving average is $262.59.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 11,250 shares of the business’s stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CMO Pushkal Garg sold 1,752 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $251.00, for a total transaction of $439,752.00. Following the sale, the chief marketing officer now directly owns 15,705 shares in the company, valued at $3,941,955. This trade represents a 10.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 72,986 shares of company stock valued at $20,397,849 in the last three months. 1.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Huntington National Bank increased its stake in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 45 shares during the period. Larson Financial Group LLC lifted its stake in shares of Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 73 shares during the period. Hollencrest Capital Management bought a new position in Alnylam Pharmaceuticals in the third quarter valued at about $29,000. R Squared Ltd acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $33,000. Finally, OFI Invest Asset Management bought a new stake in Alnylam Pharmaceuticals during the 4th quarter worth about $35,000. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.